Senseonics Holdings, Inc. Q3 2026 Earnings Recap

Senseonics reported record Q3 revenue and raised full-year guidance, while the stock rose 2.3%—a roughly flat reaction. The quarter showed accelerating commercial adoption, though the transcript also places significant future growth hopes on upcoming pump integrations and the Freedom development program.

Key Takeaways

• Q3 revenue was $19.6 million, up about 140% year over year; U.S. revenue rose about 160% to $16.8 million, and international revenue grew about 65% to $2.8 million.
• Full-year revenue guidance increased to $68 million–$70 million from $62 million–$66 million. Management said sales were running ahead of its earlier expectations.
• The company reported record shipment volume and new patient starts. Active prescribers were up over 90% year over year, and approximately 9 out of 10 new insertions came from patients switching from competing sensors.
• The Beta Bionics iLet integration is expected to launch in the coming weeks, with first patients possible before year-end; management sees it as an additional growth source in 2027.
• Freedom entered first-in-human testing on October 26. The pivotal study is expected to start in 2027, with a potential launch targeted for 2028.